{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:49:06Z","timestamp":1761630546320},"reference-count":27,"publisher":"Frontline Medical Communications, Inc.","issue":"1","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cutaneous Medicine and Surgery"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.sder.2010.02.004","type":"journal-article","created":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T13:17:13Z","timestamp":1272460633000},"page":"63-66","source":"Crossref","is-referenced-by-count":15,"title":["The Future of Biological Therapies"],"prefix":"10.12788","volume":"29","author":[{"given":"Richard B.","family":"Warren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher E.M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","reference":[{"key":"10.1016\/j.sder.2010.02.004_bib2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0140-6736(07)61129-5","article-title":"Current and future management of psoriasis","volume":"370","author":"Menter","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2010.02.004_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","article-title":"Pharmacogenomics and individualized drug therapy","volume":"57","author":"Eichelbaum","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.sder.2010.02.004_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/978-3-642-94744-5_2","article-title":"Moderne problem der humangenetik","volume":"12","author":"Vogel","year":"1959","journal-title":"Ergeb Inn Med Kinderheilkd"},{"key":"10.1016\/j.sder.2010.02.004_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10067-007-0653-7","article-title":"Polymorphism in the tumor necrosis factor-a gene promoter is associated with severity of rheumatoid arthritis in the Czech population","volume":"27","author":"Nemec","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.sder.2010.02.004_bib6","first-page":"1391","article-title":"Preliminary pharmacogenetic assessment of tumor necrosis factor (TNF) polymorphisms in psoriasis: response to anti-TNF and systemic therapies","volume":"159","author":"Tejasvi","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.004_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","article-title":"The -308 tumour necrosis factor\u2014gene polymorphism predicts therapeutic response to TNF\u2014blockers in rheumatoid arthritis and spondyloarthritis patients","volume":"46","author":"Seitz","year":"2007","journal-title":"Rheumtology"},{"key":"10.1016\/j.sder.2010.02.004_bib8","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/art.23092","article-title":"Influence of -308 A\/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis","volume":"57","author":"Guis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.004_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/tpj.2009.7","article-title":"TNF-a -308 G\/A polymorphism and responsiveness to TNF-a blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis","volume":"9","author":"O'Rielly","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.sder.2010.02.004_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-kB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.sder.2010.02.004_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2133.2006.07675.x","article-title":"A classification of psoriasis vulgaris according to phenotype","volume":"156","author":"Griffiths","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.004_bib12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/rheumatology\/41.10.1133","article-title":"Efficacy of a novel pegylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial","volume":"41","author":"Choy","year":"2002","journal-title":"Rheumatology Oxford"},{"key":"10.1016\/j.sder.2010.02.004_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd2654","article-title":"Certolizumab pegol","volume":"7","author":"Melmed","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"suppl 2","key":"10.1016\/j.sder.2010.02.004_bib14","article-title":"Golimumab, a new human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: nail, enthesitis, and dactylitis response in the randomized, placebo controlled, GO Reveal study","volume":"67","author":"Gladman","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2010.02.004_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumour necrosis factor alpha antagonist mechanism of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.sder.2010.02.004_bib16","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2010.02.004_bib17","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2010.02.004_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"A phase III, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.02.004_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2010.02.004_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2010.02.004_bib21","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.sder.2010.02.004_bib22","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4049\/jimmunol.180.3.1913","article-title":"Identification of cellular pathways of \u201ctype 1,\u201d Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis","volume":"180","author":"Haider","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.sder.2010.02.004_bib24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/eji.200535503","article-title":"IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis","volume":"36","author":"Wolk","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.sder.2010.02.004_bib25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.sder.2010.02.004_bib26","doi-asserted-by":"crossref","first-page":"10144","DOI":"10.1073\/pnas.170291697","article-title":"Human interleukin 10 related T cell derived inducible factor: molecular cloning and functional characterization as an hepatocyte stimulating factor","volume":"97","author":"Dumoutier","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sder.2010.02.004_bib27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1084\/jem.180.3.1141","article-title":"Over expression of vascular permeability factor\/vascular endothelial growth factor and its receptor in psoriasis","volume":"180","author":"Detmar","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.sder.2010.02.004_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.0022-202X.2003.22107.x","article-title":"Single nucleotide polymorphism of vascular endothelial growth factor in psoriasis of early onset","volume":"122","author":"Young","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.sder.2010.02.004_bib29","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1111\/j.1365-2230.2008.02991.x","article-title":"Complete remission of psoriasis following bevacizumab therapy for colon cancer","volume":"34","author":"Akman","year":"2009","journal-title":"Clin Exp Dermatol"}],"container-title":["Seminars in Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562910000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562910000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scmsjournal.com\/wp-content\/uploads\/2016\/01\/Vol29_i1-Future.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T15:06:55Z","timestamp":1616166415000},"score":1,"resource":{"primary":{"URL":"http:\/\/scmsjournal.com\/article\/buy_now\/?id=220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1085562910000155"],"URL":"https:\/\/doi.org\/10.1016\/j.sder.2010.02.004","relation":{},"ISSN":["1085-5629"],"issn-type":[{"value":"1085-5629","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}